All News Roivant Sciences Ltd.

Equities

ROIV

BMG762791017

Delayed Nasdaq Other stock markets 03:46:11 2024-05-17 pm EDT			5-day change	1st Jan Change
11.23 ^USD	-1.58%		+0.85%	-0.04%

Apr. 05	Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	MT
Apr. 04	Moderna Suffers Setback in Lawsuit by Arbutus	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024	May. 16	GL
Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	Apr. 05	MT
Moderna Suffers Setback in Lawsuit by Arbutus	Apr. 04	MT
Moderna shares fall after judge sides with Arbutus in patent fight	Apr. 03	RE
Deutsche Bank Raises Roivant Sciences' Price Target to $15 From $14, Maintains Buy Rating	Apr. 03	MT
Goldman Sachs Raises Roivant Sciences' Price Target to $18 From $16, Maintains Buy Rating	Apr. 03	MT
HC Wainwright Raises Roivant Sciences Price Target to $18 From $17, Maintains Buy Rating	Apr. 03	MT
Tesla, UnitedHealth Group fall; Roivant, Valero rise, Tuesday, 4/2/2024	Apr. 02	AQ
Roivant Sciences : NIU Phase 2 Topline Results	Apr. 02	PU
Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise	Apr. 02	MT
Transcript : Roivant Sciences Ltd. - Special Call	Apr. 02
Roivant Sciences Ltd. announces an Equity Buyback for $1,500 million worth of its shares.	Apr. 02	CI
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million	Apr. 02	GL
Roivant's anti-inflammatory drug succeeds in mid-stage study	Apr. 02	RE
Roivant and Priovant Therapeutics Announce Positive Results from the Phase 2 Study for Brepocitinib in NIU	Apr. 02	CI
Roivant Sciences Ltd. authorizes a Buyback Plan.	Apr. 01	CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 1000	Mar. 31	CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 400 - Biotechnology	Mar. 31	CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 400 Health Care	Mar. 31	CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P Composite 1500	Mar. 31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Roivant Sciences Ltd.

Equities

ROIV

BMG762791017

All News

Filters